EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Recruiting

Phase 1

EGFR806 CAR T CellEGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Sponsor:

Seattle Children's Hospital

Code:

NCT03618381

Conditions

Pediatric Solid Tumor

Germ Cell Tumor

Retinoblastoma

Hepatoblastoma

Wilms Tumor

Eligibility Criteria

Sex: All

Age: 1 - 30

Healthy Volunteers: Not accepted

Interventions

second generation 4-1BBζ EGFR806-EGFRt

second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Seattle Children's Hospital on 2024-04-09.